Time filter

Source Type

Mashhad, Iran

Taghavi N.,Iran National Institute of Genetic Engineering and Biotechnology | Taghavi N.,Tehran University of Medical Sciences | Biramijamal F.,Iran National Institute of Genetic Engineering and Biotechnology | Sotoudeh M.,Tehran University of Medical Sciences | And 6 more authors.
BMC Cancer | Year: 2010

Background: Tumor suppressor genes p53 and p16INK4aand the proto-oncogene MDM2 are considered to be essential G1 cell cycle regulatory genes whose loss of function is associated with ESCC carcinogenesis. We assessed the aberrant methylation of the p16 gene and its impact on p16INK4aprotein expression and correlations with p53 and MDM2 protein expressions in patients with ESCC in the Golestan province of northeastern Iran in which ESCC has the highest incidence of cancer, well above the world average.Methods: Cancerous tissues and the adjacent normal tissue obtained from 50 ESCC patients were assessed with Methylation-Specific-PCR to examine the methylation status of p16. The expression of p16, p53 and MDM2 proteins was detected by immunohistochemical staining.Results: Abnormal expression of p16 and p53, but not MDM2, was significantly higher in the tumoral tissue. p53 was concomitantly accumulated in ESCC tumor along with MDM2 overexpression and p16 negative expression. Aberrant methylation of the p16INK4agene was detected in 31/50 (62%) of esophageal tumor samples, while two of the adjacent normal mucosa were methylated (P < 0.001). p16INK4aaberrant methylation was significantly associated with decreased p16 protein expression (P = 0.033), as well as the overexpression of p53 (P = 0.020).Conclusions: p16 hypermethylation is the principal mechanism of p16 protein underexpression and plays an important role in ESCC development. It is associated with p53 protein overexpression and may influence the accumulation of abnormally expressed proteins in p53-MDM2 and p16-Rb pathways, suggesting a possible cross-talk of the involved pathways in ESCC development. © 2010 Taghavi et al; licensee BioMed Central Ltd. Source

Hashem Dabaghian F.,Tehran University of Medical Sciences | Abdollahifard M.,Tehran University of Medical Sciences | Khalighi Sigarudi F.,Omid Hospital | Taghavi Shirazi M.,Tehran University of Medical Sciences | And 4 more authors.
Journal of Medicinal Plants | Year: 2015

Background: Rosa canina L. (rose hip) has been traditionally used to treat diabetes mellitus in Iran. However, no scientific human study has determined its efficacy in diabetic patients. Objective: This study was conducted to evaluate the efficacy and safety of R. canina fruit aqueous extract in type 2 diabetic patients. Methods: Sixty patients with type 2 diabetes, aged 35-60 years with fasting blood glucose levels between 130 to 200 mg/dL and HbA1c between 7-9% despite using conventional oral hypoglycemic drugs were divided randomly to two groups. Two groups of 25 and 23 patients completing the trial received 750 mg R. canina fruit extract and 750 mg toast powder as placebo two times a day respectively for three months. Fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) as primary outcomes and postprandial blood glucose (PBG), lipid profile and hepatic and renal function tests as secondary outcomes were determined at baseline and at endpoint of treatment. The patients were asked to note down any gastrointestinal or other side effects during the study. Results: The FBG level decreased significantly (P = 0.002) in R. canina group after 3 months compared to the baseline. In addition total cholesterol/HDL-C was significantly (P = 0.02) decreased in the R. canina group compared to the baseline. Other blood parameters were not significantly changed during the study compared with placebo and baseline. No serious side effects were reported in both groups during the study. Conclusion: Rosa canina 3-month administration to type 2 diabetic patients may reduce fasting blood glucose and total cholesterol/HDL-C without any side effect. Source

Delirezh N.,Urmia University | Majedi L.,Urmia University | Rezaei S.A.,Urmia University | Ranjkeshzadeh H.,Omid Hospital
Iranian Biomedical Journal | Year: 2011

Background: Dendritic cells (DC) induce tumor or pathogen-specific T cell responses in humans. Several laboratories have developed culture systems, including maturation factors for human DC from peripheral blood monocytes. We comprehensively compared standard maturation stimulus, an autologous monocyte-conditioned medium (MCM), with heparin for their ability to promote uniformly mature DC that elicit T cell responses. Methods: A short (4-day) priming of plastic adherent monocytes with granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4 with or without heparin was followed by 48-hour incubation in MCM to generate fully mature and stable DC. Phenotypic and functional analyses were carried out using anti-CD14 and anti-CD83 monoclonal antibodies, and mixed lymphocyte reaction, respectively. Results: We found that fully matured DC with a large amount of cytoplasm and copious dendritic projections were visible at the end of culturing period in the presence of MCM, heparin and MCM plus heparin. Thus, DC generated with these maturation factors are nonadherent and have typical satellite morphology. Flow cytometric analysis using anti-CD14 (monocyte marker) and anti-CD83 (mature DC marker) revealed that expression of CD14 decreased in MCM plus heparin-treated DC, and the expression of CD83 was increased when heparin and MCM used as a maturation factor. Functionally, MCM and MCM plus heparin-treated DC showed stronger mixed leukocyte reaction than heparin alone. Conclusion: These results support the use of the MCM with heparin as maturation factor that could result in functionally mature monocyte-derived DC in comparison to either MCM or heparin alone. Source

Majidi M.R.,Mashhad University of Medical Sciences | Nourizadeh N.,Mashhad University of Medical Sciences | Ghafarzadegan K.,Omid Hospital | Shahriari S.,Mashhad University of Medical Sciences | Shakeri M.,Mashhad University of Medical Sciences
Indian Journal of Otolaryngology and Head and Neck Surgery | Year: 2012

The aim of this study was to evaluate the effect of surgery on the histology of nasal mucosa in patients with nasal polyposis and the comparison/also to compare it with normal population. This case-control study was conducted on 20 patients at the Otorhinolaryngology-Head and Neck Surgery Department, Qaem Hospital, Mashhad University of Medical Sciences during October 2007 to June 2008. Patients with polyposis and patients with septal deviation who were candidate for septoplasty were considered as case and control groups, respectively, including 10 subjects in each. Specimens of polyp tissue and the inferior conchae (mucosa) were taken during sinus endoscopy from the case group. One month later, another specimen was taken from the inferior conchae (mucosa). Moreover, specimens of the inferior conchae (mucosa) were taken of the control group. Percentage of goblet cells among the epithelial cells was determined for each group. Goblet cell percentage found to be 15.7% in polyps, consistent with significant difference with that of in postoperative (13.3%) and in preoperative nasal mucosa specimens (39.86%), (P = 0.043 and P = 0.03, respectively). Goblet cell percentage was 39.86% and 4.9% in the case and control groups, in that order, which were significantly high (P < 0.001). Percentage of goblet cells showed to be lower in polyps than mucosa. Also percentage of goblet cells in postoperative nasal mucosa specimens was significantly lower than preoperative specimens. Therefore, surgery has additional benefit of histological improvement rather than opening nasal airway. © 2011 Association of Otolaryngologists of India. Source

Dadkhah E.,Mashhad University of Medical Sciences | Dadkhah E.,George Mason University | Naseh H.,Omid Hospital | Farshchian M.,Mashhad University of Medical Sciences | And 10 more authors.
Archives of Iranian Medicine | Year: 2013

Background: Esophageal squamous cell carcinoma (ESCC) is the second-most frequently diagnosed cancer in Northeast Iran, often diagnosed in advanced stages. No standard early diagnostic guideline has been proposed to date and current therapeutic modalities are not effective. Detection of tumor-specific biomarkers, which is the goal of this study, could prove useful in the diagnosis of ESCC. Methods: To better understand the gene expression profile of ESCC, we analyzed tumor samples and corresponding adjacent normal tissue from ESCC patients by Chemiluminescent Human Cancer GEArrays. Candidate genes were verified by real-time PCR. Results: Out of 440 cancer-related genes included in the array, 71 were overexpressed compared to normal tissue, with significant differences in 11 genes. There were 108 genes underexpressed, with significant differences in 5 genes. Until now, the AP2M1, FTL, UBE2L6, HLA-C, and HSPA8 overexpressed genes and XRCC5, TP53I3 and RAP1A underexpressed genes were not reported in ESCC. We chose the MMP2, HLA-G, and XRCC5 markers from 58 Iranian ESCC patients to verify the expression validity by real-time PCR. The microarray results were confirmed with two-tailed significance levels of P = 0.003 (MMP2), P = 0.000 (HLA-G) and P = 0.002(XRCC5). Analysis performed for the candidate genes using GNCpro online software highlighted two pathways, an immuno-modulatory response and DNA replication and repair. We successfully performed and validated Chemiluminescent GEArray gene expression profiling in ESCC. Several biomarkers that might be related to tumorigenesis in ESCC were identified. Conclusion: Immuno-modulatory and DNA repair pathways could be used as targets to locate specific diagnostic, prognostic, and therapeutic biomarkers for ESCC. Source

Discover hidden collaborations